The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields.
 
Mario E. Lacouture
Stock and Other Ownership Interests - Oncoderm (I)
Honoraria - Apricity Health; AstraZeneca; Deciphera; Incyte; Innovaderm; Janssen; L'Oreal; La Roche-Posay; Lutris; MJH Associates; Nanology; Novartis; Novocure; OnQuality Pharmaceuticals; RBC consultants; Relay Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Tyra Biosciences
Consulting or Advisory Role - Apricity Health; AstraZeneca; Deciphera; Genentech; Incyte; Innovaderm; Janssen Research & Development; La Roche-Posay; Lutris; Novartis; Novocure; OnQuality Pharmaceuticals; Relay Therapeutics; Roche; Roche; Seagen; Tyra Biosciences
Research Funding - AstraZeneca/MedImmune (Inst); Columbia University (Inst); Lutris; National Jewish Health (Inst); Novartis (Inst); Novocure; Paxman; US Biotest
Other Relationship - Oncoderm (I)
(OPTIONAL) Uncompensated Relationships - Oncoderm
 
Kwami Ketosugbo
No Relationships to Disclose
 
Stephen W Dusza
No Relationships to Disclose
 
Samuel A. Goldlust
Employment - Regional Cancer Care Associates
Leadership - Cellevolve
Stock and Other Ownership Interests - COTA
Honoraria - Cornerstone Specialty Network; Daiichi Sankyo/Astra Zeneca; Physicans' Education Resource
Consulting or Advisory Role - Boston Biomedical; Cellevolve; Novocure; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Novocure
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Cantex Pharmaceuticals (Inst); Celgene (Inst); Celldex (Inst); Celularity (Inst); CNS Healthcare (Inst); Cortice Biosciences (Inst); Diffusion Pharmaceuticals (Inst); ImmunoCellular Therapeutics (Inst); Imvax (Inst); Imvax (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Novogen (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Tocagen (Inst); Wex Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Kyowa Kirin International; Novocure
 
Priya Kumthekar
Stock and Other Ownership Interests - EnClear Therapies; Vivacitas Oncology
Consulting or Advisory Role - Affinia Therapeutics; Biocept; BioClinica; ElevateBio; EnClear Therapies; Janssen; Novocure; Orbus Therapeutics; SDP Oncology; Sintetica
Research Funding - Angiochem; DNAtrix; Genentech; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Gennao Bio; Guidepoint Global; Kiyatec; Massive Bio; Medtronic; Merck; MimiVax; Novocure; PPD; Regeneron; tocagen; Xcures
Speakers' Bureau - Prime Oncology
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); FORMA Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Sapience Therapeutics (Inst); tocagen (Inst)
Travel, Accommodations, Expenses - Oncoceutics
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics